Company profile
Edgewise Therapeutics, Inc.
Pipeline4 assets
- SevasemtenMyosin ATPase / Oral fast skeletal myosin inhibitor / Muscular dystrophyBecker muscular dystrophyPivotal / Phase 3Duchenne muscular dystrophyPhase 2
- EDG-7500EDG-7500 / Undisclosed cardiac sarcomeric target / Oral selective cardiac sarcomere modulator / CardiovascularHypertrophic cardiomyopathyPhase 2
- EDG-15400EDG-15400 / Undisclosed cardiac sarcomeric target / Oral selective cardiac sarcomere modulator / CardiovascularHFpEFPhase 1
- EDG-003EDG-003 / Undisclosed target / CardiometabolicCardiometabolicPreclinical